AIS Healthcare

What AIS Healthcare does

AIS Healthcare is a Dallas-headquartered, privately held specialty healthcare company operating two divisions: Advanced Infusion Care (AIC) and Targeted Drug Delivery (TDD). AIC dispenses in-home and infusion-center immunoglobulin (IVIg/SQIg) and Alpha-1 antitrypsin therapies, supported by 300+ employed registered nurses credentialed as Advanced Nursing Solutions, with 97% patient adherence and 99% patient satisfaction reported; the division also operates five outpatient Advanced Infusion Care Centers (Phoenix, Atlanta, Marietta, Louisville, Dallas) and holds limited distribution rights for multiple Ig brands including YIMMUGO, ALYGLO, Asceniv, Cutaquig, Cuvitru, Gammaplex, Hyqvia, and Xembify. TDD operates two fully redundant state-of-the-art 503A compounding pharmacies that prepare and ship more than 145,000 patient-specific intrathecal prescriptions annually using a proprietary process combining aseptic processing with terminal sterilization to achieve higher sterility assurance and extended Beyond-Use Dates; medications ship to physician offices or patient homes via per diem billing under Medicare Part B and commercial insurance.

The company is dually accredited by URAC and the Accreditation Commission for Health Care, holds CMS DMEPOS supplier accreditation, dispenses from six pharmacy locations (Ridgeland MS, Valdosta GA, Birmingham AL, Panama City FL, Cockeysville MD, Garden Grove CA), and serves patients across the United States through physician referrals, a Financial Concierge Team for insurance navigation, and the MyAIS Connect patient portal. AIS Healthcare was founded in 1998, employs 101–250 corporate staff in addition to the nursing workforce, and is led by CEO Simon Castellanos with division leadership including Jud Hall (President, AIC). Recent strategic activity has centered on a Premier, Inc. group purchasing agreement effective July 1, 2025, the acquisition of Preferred Excellent Care (Garden Grove, CA), four new infusion center openings in late 2025 / first half of 2026, the addition of Kedrion Biopharma's YIMMUGO to the Ig portfolio, and the appointment of Sybil Rajan as Chief Legal and Compliance Officer in May 2026.

Name

AIS Healthcare

Legal name

AIS Healthcare

Website

https://aiscaregroup.com

Company type

Private

Founded year

1998

Operating status

Operating

Headcount range

101–250 employees

Short description

AIS Healthcare is a Dallas-based, privately held specialty healthcare company operating two divisions — Advanced Infusion Care (in-home and infusion-center Ig and Alpha-1 therapy) and Targeted Drug Delivery (503A compounded intrathecal medications) — serving patients with primary immunodeficiency, rare diseases, and chronic pain nationwide through 300+ employed nurses and multiple pharmacy and infusion center locations.

Ownership category

akta.pro rank

Product category

Specialty Pharmacy and Infusion Services

NAICS

All Other Outpatient Care Centers (621498)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Health Services (8000)

akta.pro primary industry

Infusion & Home Infusion Pharmacy Services (HLAFALAG)

akta.pro secondary industries

Home Infusion Therapy Providers (HLAFAEAE), Infusion Therapy Centers (Outpatient) (HLAFABAF), IV Therapy, Infusion & Injection Services (Home-Based) (HSABACAF), Home Infusion Therapy & IV Nursing Services (HLADAFAG), In-Home Infusion Pharmacy Support & Coordination (HSABALAH)

Keywords

• Specialty pharmacy services
• Infusion therapy
• Targeted drug delivery
• Compounding pharmacy
• Home infusion nursing

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices11 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Infrastructure, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

1. Specialty Pharmacy Dispensing - Infusion Care: AIC dispenses immunoglobulin (Ig), Alpha-1, and other specialty medications to patients in home infusion and infusion center settings. The company bills health insurance providers directly for medication and services.
2. Per Diem Billing - Targeted Drug Delivery: AIS Healthcare charges per diem rates for each day a patient's implanted infusion pump is infusing medication. Per diems are industry-standard charges that help defray compounding costs including care coordination, pharmacy support, safety and quality testing (terminal sterilization), and nationwide shipping. Per diems are the preferred billing method for TDD therapy by many insurance companies.
3. Insurance and Medicare Part B Billing: The company bills health insurance providers directly for all medication and services, including Medicare Part B. Patients may have cost-share obligations. The Financial Concierge Team navigates insurance coverage for both in-network and out-of-network patients, as well as Medicare, Medicaid, and self-pay patients.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

AIS Healthcare operates two divisions: Advanced Infusion Care (AIC) provides in-home and infusion-center immunoglobulin (Ig) and Alpha-1 therapies through 300+ certified nurses, while Targeted Drug Delivery (TDD) prepares patient-specific compounded medications for surgically implanted intrathecal infusion pumps via two 503A compounding pharmacies shipping over 145,000 prescriptions annually. The company bills health insurance providers (including Medicare Part B) directly for medications and services, and assists patients with insurance authorization through its Financial Concierge Team.

Product overview

AIS Healthcare operates two main divisions: Advanced Infusion Care (AIC) and Targeted Drug Delivery (TDD). AIC specializes in in-home immunoglobulin (Ig) and Alpha-1 therapy delivery through 300+ experienced nurses, and operates multiple Advanced Infusion Care Centers (AICC) across the US. AIC offers a portfolio of limited-distribution Ig products including YIMMUGO, ALYGLO, Asceniv, Cutaquig, Cuvitru, Gammaplex, HyQvia, and Xembify. TDD provides patient-specific 503A compounded medications for surgically implanted intrathecal infusion pumps, operating two state-of-the-art compounding pharmacies that ship 145,000+ prescriptions annually. The company provides additional services including nursing care, billing/financial support through a Financial Concierge Team, and a patient portal (MyAIS Connect).

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Infusion Care (AIC) Division offering in-home immunoglobulin (Ig) and Alpha-1 therapy, plus access to FDA-approved treatments in infusion centers. Provides a Center of Excellence approach with team-based model prioritizing patient outcomes.
• Targeted Drug Delivery (TDD) Division providing patient-specific compounded medications and services for individuals with surgically implanted intrathecal infusion pumps. Operates two fully redundant state-of-the-art 503A compounding pharmacies that dispense over 145,000 prescriptions annually.
• AIC Home Infusion In-home infusion care delivering Ig and Alpha-1 therapies via 300+ experienced nurses, with 24/7 clinical support and streamlined patient onboarding process. Patients are contacted 24-48 hours before each infusion, and medications are delivered to the home.
• Advanced Infusion Care Centers (AICC) Outpatient infusion centers offering flexible scheduling, private treatment rooms, and expert clinical care across multiple specialties including neurology, gastroenterology, dermatology, immunology, pulmonology, ophthalmology, and endocrinology.
• 503A Intrathecal Compounding Pharmacy Specialty compounding pharmacy preparing and shipping 145,000+ patient-specific prescriptions annually using aseptic processing combined with terminal sterilization to achieve higher sterility assurance and extended Beyond-Use Dates compared to industry standards.
• AIC Nursing Services In-home infusion nursing delivered by 300+ certified nurses (credentialed as Advanced Nursing Solutions) providing IV and subcutaneous medication administration, with 99% patient satisfaction rate and 24/7 access to clinical support. 98% of patients receive care from an AIC-employed nurse.
• Clinic Connect TDD service connecting clinics with AIS Healthcare pharmacy and nursing services for patients with implanted pain pumps, providing a direct link for physicians to access compounded intrathecal medications and supporting care.
• Financial Concierge Team (FCT) Billing and insurance navigation support helping patients understand invoices, work with insurance companies (including Medicare, Medicaid, in-network and out-of-network), and access financial assistance programs.
• MyAIS Connect Patient Portal Online patient portal for managing prescriptions, viewing medical records, and accessing AIS Healthcare services. Complemented by a physician portal at myaisconnect.com for provider-based care management.

Quantifiable outcome

• 97% patient medication adherence rate
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered core.

• Kedrion BiopharmacoreStrategic or Co-development Partner · 20 October 2025AIC, a division of AIS Healthcare, now offers YIMMUGO (immune globulin intravenous human-dira, 10% liquid), manufactured by Kedrion Biopharma, for the treatment of primary humoral immunodeficiency in patients 2 years of age and older. AIS Healthcare is a specialty pharmacy limited distribution network member providing exclusive access to this IVIg treatment option nationwide.
• Premier, Inc.coreChannel Partner/ Reseller/ Distributor · 1 July 2025AIS Healthcare was awarded a group purchasing agreement for 503A intrathecal compounded medications with Premier, Inc., effective July 1, 2025. The agreement allows Premier's more than 4,400 U.S. hospital and health system members to access AIS Healthcare's sterile, patient-specific intrathecal pain pump medications at special pricing and terms pre-negotiated by Premier. Premier provides site audit evaluations and ongoing quality reporting to member hospitals to assist with compliance policies.

Scale indicators7 records

Recent moves11 records

Expansion highlights5 records

Direct peers

• BioMatrix Specialty Pharmacy: National specialty pharmacy focused on infusion, injectable, and oral specialty therapies for chronic conditions including immunology, neurology, and rheumatology. Overlaps directly with AIC's home infusion and limited-distribution Ig offerings.
• Soleo Health: Privately held specialty infusion services provider offering in-home and alternate-site infusion of specialty biologics (Ig, biologics, nutrition) with similar referral-driven GTM. Directly comparable in scale, service mix, and patient population to AIS Healthcare's AIC division.
• Palmetto Infusion Services: Multi-site outpatient and home infusion provider based in the Southeast U.S. Directly overlaps with AIC's infusion center and home infusion offerings in a similar geographic footprint.
• Amerita: National home infusion pharmacy provider owned by BrightSpring, offering specialty infusion therapies for chronic conditions. Comparable to AIC's home infusion model and patient mix (Ig, biologics, nutrition).
• KabaFusion: Specialty home infusion pharmacy with national reach focused on immune globulin therapies and chronic inflammatory conditions. Closely aligned business model and patient population with AIC's home infusion Ig services.
• Option Care Health: Largest independent U.S. provider of home and alternate-site infusion services, with comparable Ig, Alpha-1, and specialty infusion offerings plus national pharmacy and nursing infrastructure. Most direct public-market comparable for AIS Healthcare's AIC division.

Broad incumbents

• Coram CVS Specialty Infusion Services: National home infusion and specialty pharmacy division of CVS Health, one of the largest U.S. infusion providers. Represents a major competitor and structural incumbent whose vertical integration with CVS Caremark pressures AIS Healthcare's reimbursement and network access.
• Diplomat Pharmacy (now Optum Specialty Pharmacy): Specialty pharmacy historically focused on Ig, oncology, and chronic disease therapies; now part of Optum. Directly comparable to AIC's specialty pharmacy and limited-distribution Ig distribution model.
• Optum Infusion Pharmacy / Optum Specialty: Optum's home infusion and specialty pharmacy businesses, part of UnitedHealth Group. Direct overlap with both AIC (specialty/home infusion) and TDD (specialty pharmacy) plus vertically integrated payer relationships.
• Walgreens Specialty Pharmacy: National retail-affiliated specialty pharmacy offering Ig and specialty infusion therapies. Competes with AIC for limited-distribution Ig manufacturer contracts and patient referrals, particularly through community pharmacy channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights8 records

Customer concentration

• Xx.com/AISHealth
• LinkedInlinkedin.com/company/advanced-infusion-solutions

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AIS Healthcare